Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 301–400 of 657
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
“injections and site reactions cannot be ruled out, the risk appears to be small, especially in comparison to exenatide ER (which was reported at 22% in the head-to-head trial with semaglutide) [14].”
BackgroundGLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Peng, D., Yang, L., Si, L., Zhu, B., Wu, P., Li, Y., Tang, D., Liu, Y., & Zhang, Y. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106477 · Cited by 17
Formichi, C., Baronti, W., Gennaro, G., Ceroni, M. C., Nigi, L., Rizzo, L., & Dotta, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02369-4 · Cited by 17
Self-citationPractical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Larsen, A. T., Melander, S. A., Sonne, N., BREDTOFT, E.-M., Al-Rubai, M., Karsdal, M. A., & Henriksen, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114969 · Cited by 17
Shabutdinova, O. R., Dautov, A. R., Samkov, A. A., Kononenko, A. V., Sargaliev, A. F., Davletshin, A. R., Andresova, P. A., Zarbeeva, K. R., Torshkhoeva, D. A., Rakhmonkulov, U. A., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13197 · Cited by 18
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01516-z · Cited by 16
Tan, X., Divino, V. M., Amamoo, J. J., Xie, L., Coyle, K. B., Gamble, C. L., Guevarra, M., Paprocki, Y., & King, A. A. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01354-2 · Cited by 16
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Vidal, J., Malkin, S. J. P., Hunt, B., Martín, V., Hallén, N., & Ortega, F. J. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00751-7 · Cited by 16
Tham, L. S., Pantalone, K. M., Dungan, K. M., Munir, K. M., Tang, C. C., Кониг, М., & Kwan, A. Y. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14582 · Cited by 16
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01347-0 · Cited by 16
Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1860022 · Cited by 15
Gokul, P. R., Apperley, L. J., Parkinson, J., Clark, K., Lund, K., Owens, M., & Senniappan, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000537921 · Cited by 15
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Hayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 15
de la Flor, J. C., Lorenzo, J. D., Marschall, A., Valga, F., Monzón, T., & Cícero, E. R. (2022) · Case Reports in Nephrology and Dialysis · doi:10.1159/000527919 · Cited by 15
Wełnicki, M. T., Gorczyca-Głowacka, I., Mamcarz, A., Filipiak, K. J., Wożakowska−Kapłon, B., Barylski, M., Szymański, F. M., Kasprzak, J. D., Grabowski, M., & Dzida, G. J. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0282 · Cited by 15
Evans, M., Berry, S., Malkin, S. J. P., Hunt, B., & Sharma, A. K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01408-2 · Cited by 15
Malkin, S. J. P., Russel-Szymczyk, M., Psota, M., Hlavinkova, L., & Hunt, B. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00965-y · Cited by 15
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 15
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14701 · Cited by 14
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Aroda, V. R., Frías, J. P., Ji, L., Niemoeller, E., Nguyên‐Pascal, M., Denkel, K., Espinasse, M., Guo, H., Baek, S. J., Choi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15079 · Cited by 14
Self-citationXie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Zu, N., & Shi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15624 · Cited by 14
Wong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 15
Bzowyckyj, A. S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13229 · Cited by 14
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 15
Sani, E., Prato, G. D., Zenti, M. G., Bordugo, A., Trombetta, M., & Bonora, E. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220509225637 · Cited by 14
Dang, L. E., Fong, E., Tarp, J. M., Clemmensen, K. K. B., Ravn, H., Kvist, K., Buse, J. B., van der Laan, M. J., & Petersen, M. L. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.656 · Cited by 15
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 14
Johansen, P., Hunt, B., Iyer, N. N., Dang‐Tan, T., & Pollock, R. F. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00915-8 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Ruan, Z., Ung, C. O. L., Shen, Y., Zhang, Y., Wang, W., Luo, J., Zou, H., Xue, Y., Wang, Y., Hu, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01301-4 · Cited by 14
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists?
Guja, C., & Miulescu, R. D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.09 · Cited by 14
Klein, M. P., Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241245680 · Cited by 13
Sun, Y., Lu, B., Hu, Y.-W., Lv, Y., & Zhong, S. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s477497 · Cited by 12
Sørensen, K. K., Gerds, T. A., Køber, L., Fosbøl, E. L., Poulsen, H. E., Møller, A. L., Andersen, M. P., Pedersen‐Bjergaard, U., Torp-Pedersen, C. T., & Zareini, B. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70000 · Cited by 13
Carminati, M., Tondello, M., Concina, A., Olgiati, P., & Zanardi, R. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000595 · Cited by 13
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
As, A., Шохин, И. Е., Rogozhina, E. A., Геннадьевна, Б. Т., Nevretdinova, M. E., Bely, P. A., Zaslavskaya, K. Y., Shcherbakova, V. S., Куркин, Д. В., Koryanova, K. N., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-324-346 · Cited by 13
Shi, F., Li, H., Cui, M., Zhang, Z.-L., Gu, Z., & Liu, X.-Y. (2018) · Medicine · doi:10.1097/md.0000000000010420 · Cited by 13
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 12
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting
Conti, M., Pontiggia, L., Vergani, M., Muraca, E., Cannistraci, R., Perra, S., Lattuada, G., Perseghin, G., & Ciardullo, S. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02424-9 · Cited by 12
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Lafarge, J.-C., Aron‐Wisnewsky, J., Pattou, F. N., Cucherat, M., Blondet, E., Lascols, S., Guludec, D. L., David, D.-J., & Carbonneil, C. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101495 · Cited by 12
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 13
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“0 mg to weekly exenatide 2 mg [29]; semaglutide was superior for HbA1c reduction (–1.”
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 12
Jacobson, S., Margolese, N., & Margolese, H. C. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251386626 · Cited by 11
Lee, B., Cho, Y. M., Kim, S. G., Ko, S., Lim, S. K., Dahaoui, A., Jeong, J. S., Lim, H. J., & Yu, J. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01515-0 · Cited by 11
Huang, X., Wu, M., Lin, J., Mou, L., Zhang, Y., & Jiang, J. (2024) · Medicine · doi:10.1097/md.0000000000038236 · Cited by 11
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Johansen, P., Sandberg, A., & Capehorn, M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01242-z · Cited by 11
Self-citationDalmazi, G. D., Coluzzi, S., BALDASSARRE, M. P. A., Sorbo, S. E., Dell’Aquila, S., Febo, F., Ginestra, F., Graziano, G., Rossi, M. C., Consoli, A., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.002 · Cited by 11
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Rodriguez, P., Breslaw, N., Xiao, H., Bena, J., Jenkins, K., Isaacs, D. M., Zhou, K., Griebeler, M. L., Burguera, B. G., Pantalone, K. M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16057 · Cited by 10
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
Semaglutide once-weekly: improved efficacy with a new safety warning
Coon, S. A., Crannage, E. F., Kerwin, L. C., & Guyton, J. E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1534201 · Cited by 10
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction
Palazzuoli, A., Severino, P., D’Amato, A., Myftari, V., Tricarico, L., Correale, M., Dattilo, G., Fioretti, F., & Nodari, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507270 · Cited by 10
Alenzi, S., Alzahrani, A., Aljaloud, A., Alanazi, K., & Alarfaj, S. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395651 · Cited by 10
Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
Patel, D. K. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000112 · Cited by 10
Berković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Hu, S., Su, X., Deng, X., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701446 · Cited by 10
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 10
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
de Freitas, G. C. P. L., Vasconcelos, M. C. D. H. V., Bisneta, A. I. S., Parra, R. L. O., Pereira, M. E. B., Negreiros, M. E. L., Toledo, M. B., Alves, G. C., & Sobrinho, F. E. R. A. (2023) · Research Society and Development · doi:10.33448/rsd-v12i4.40955 · Cited by 9
Chen, S.-Y., Telfser, A. J., Olzomer, E. M., Vancuylenberg, C. S., Zhou, M., Beretta, M., Li, C., Alexopoulos, S. J., Turner, N. A., Byrne, F. L., et al. (2024) · Clinical Science · doi:10.1042/cs20231016 · Cited by 9
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
Zangabad, P. S., Vasani, R. B., Tong, Z., Anderson, D., Rudd, D. A., Hick, C. A., Wootten, D. L., Sexton, P. M., Yan, L., Esser, L., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400136 · Cited by 9
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
Jiang, W., Wang, Q., Zhang, X., Yang, H., & Yang, X. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106793 · Cited by 9
Ruan, Z., Jiang, Y., Shi, H., Jia, R., Ung, C. O. L., & Hu, H. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174099 · Cited by 10
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100082 · Cited by 9
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Winkler, G., Hajós, P., & Kis, J. T. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31615 · Cited by 8
Ji, L., Ahmann, A., Åhrén, B., Capehorn, M., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., & SORLI, C. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15309 · Cited by 8
Self-citationSemaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 8
Medical treatment of obesity: Modern approaches and prospects
Titova, V. V., Омариевна, У. Ф., & Demidova, T. Y. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-4-18 · Cited by 8
Nekidy, W. S. E., Hasan, H., Abidi, E., Sayegh, L. A., Dajani, R. Z., El-Kaissi, S., Hegazin, S. B., & Mallat, J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251340645 · Cited by 8
Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review
Teague, M., Martinez, A., Walker, E., El-Rifai, M., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.003 · Cited by 8
Ryder, B., & DeFronzo, R. A. (2019) · British Journal of Diabetes · doi:10.15277/bjd.2019.207 · Cited by 8
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
Powell, J., Piszczatoski, C., & Taylor, J. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.017 · Cited by 8
Sex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
Kan, R., Wang, S., Meng, X., Guo, Y., Li, D., & Yu, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01995-z · Cited by 7
Chen, J.-J., Hsu, C., Hung, C., Suen, M.-W., Wang, H.-Y., Yang, W.-C., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020608 · Cited by 7
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.